GLP-1 TV · Clinician
Dr Explains The Ozempic Pill Foundayo- Better Than Peptide Shots?
Today’s cheapest semaglutide pill$199/mo at RxSpan MD on a 6-month plan.Compare all semaglutide pill prices Price read 14 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
In this video, the speaker, a primary care physician, discusses Foundayo, the brand name for orforglipron, which she says launched in April 2026 through Eli Lilly. She explains that it is a GLP-1 receptor agonist like semaglutide, but it is a small molecule rather than a peptide, so the stomach does not treat it like food. According to her, that lets it be taken with or without food and at any time, unlike oral semaglutide (Rybelsus), which she describes as fragile, with strict water and timing rules and variable absorption.
Published by This Is Not Covered - Dr. Ashley Froese on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
She says the weight loss seen in studies is around 12 to 15%, similar to semaglutide, compared with 20 to 22% for tirzepatide. She also describes retatrutide as a triple agonist that is not approved for human use, and says the glucagon component may help prevent metabolism from slowing during weight loss. Her conclusion is that the pill wins on convenience while the injectables win on potency. She says it can be a good fit for people who avoid GLP-1s because of needles, but people already doing well on tirzepatide should think carefully before switching.
On safety, she says trials enrolled over 4,500 people. At doses around 9 mg and above, she reports more nausea, constipation and diarrhea, with about 10% of the highest-dose users stopping. She also mentions hair thinning in about 5% of users, a thyroid cancer black box warning, pancreatitis, gallstones, kidney injury risk from low fluid intake, and low sodium with fatigue. After a sponsor segment for Element, she gives Lilly Direct cash prices of about $149 a month for the 0.8 mg starting dose and $349 a month for the highest dose. She closes by urging resistance training and enough protein. She notes this is not medical advice.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:30 The speaker says Foundayo is the brand name for orforglipron, launched in April 2026 through Eli Lilly, and is a GLP-1 receptor agonist.
- 1:01 She explains it is a small molecule rather than a peptide, so it can be taken with or without food, unlike oral semaglutide.
- 3:32 She cites about 12 to 15% weight loss for single agonists like Foundayo and semaglutide versus 20 to 22% for tirzepatide, concluding injectables still win on potency.
- 5:39 She reports more nausea, constipation and diarrhea at doses around 9 mg and above, with about 10% of top-dose users stopping.
- 6:43 She lists hair thinning in about 5% of users, a thyroid cancer black box warning, pancreatitis and gallstone risks, and kidney injury risk from low fluid intake.
- 8:43 She gives Lilly Direct cash prices of about $149 a month at 0.8 mg up to $349 a month at the highest dose.
Key moments
Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Ozempic, Wegovy, Rybelsus and Foundayo
- Side effects mentioned
- nausea, constipation and gallbladder
Questions this video answers
Is Foundayo (orforglipron) a peptide like Ozempic?
According to the speaker, no. She says it is a small molecule, not a peptide and not semaglutide, so the stomach does not digest it like food. She says this lets it be absorbed reliably with or without food.
How much weight loss does Foundayo show compared with tirzepatide?
The speaker says the studies show around 12 to 15% weight loss for Foundayo, similar to semaglutide. She says tirzepatide shows 20 to 22% average weight loss in studies.
How much does Foundayo cost through Lilly Direct?
The doctor says the 0.8 mg starting dose is around $149 a month and the highest dose is $349 a month. She compares the top price to injectable Ozempic or Wegovy, and says it is less than tirzepatide or Zepbound.
What side effects of Foundayo does the doctor mention?
She mentions nausea, constipation and diarrhea, which she says rise above about 9 mg, and hair thinning in about 5% of users. She also notes a thyroid cancer black box warning and risks of pancreatitis, gallstones and kidney injury.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Foundayo (Orforglipron): Is This GLP-1 Pill Really Better Than Ozempic Shots?According to the video, Foundayo (orforglipron) is a once-daily oral GLP-1 for weight loss that the FDA has approved.
New Weight Loss Pill That Replaces Ozempic? - Foundayo ReviewThe speaker reviews Foundayo (the captions spell it Foundeo), the brand name for orforglipron.
Ozempic Pill? Everything You Need to Know about Orforglipron | Breaking down the dataThe speaker says orforglipron is the first oral small molecule GLP-1 receptor agonist to get this far in clinical trials.
Foundayo: The First GLP-1 Pill Explained (FDA Approved 2026)According to the video, the FDA approved Foundayo (orforglipron), a once-daily tablet from Eli Lilly, on April 1st, 2026.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Semaglutide for weight loss: which version, and what each costs
Semaglutide is the molecule. For weight loss the FDA-approved version is Wegovy, sold as a weekly pen and a daily tablet. Ozempic is the same molecule approved for type 2 diabetes, so using it for weight is off-label. Compounded semaglutide uses semaglutide as its active ingredient, comes from a compounding pharmacy, is not FDA-approved, and is what most cash buyers actually take because it costs a fraction of the brand. All three produce the same side effects. What differs is the approval, the oversight and the price.
- Mounjaro vs Ozempic, and the trial everyone quotes about it
Mounjaro is tirzepatide and Ozempic is semaglutide: different molecules, not two brands of the same drug. Both are approved for type 2 diabetes, and the weight-loss versions are Zepbound and Wegovy. In the one head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% mean body-weight loss at 72 weeks against semaglutide's 13.7%. The detail almost every page omits: that trial dosed semaglutide to 2.4 mg in people without diabetes, which is the Wegovy range. Ozempic tops out at 2 mg. The famous result did not test Ozempic's dose range.
- Foundayo: the GLP-1 pill where buying direct is the cheap route
Lilly's oral GLP-1 was approved on 1 April 2026, and it does something no other weight-loss pill does: you take it any time of day, with or without food. The pricing is the surprising part. Lilly self-pay starts at $149 a month, and the one telehealth program on our board selling it, Sesame Care, charges $208 once its membership fee is counted. That reverses the usual arithmetic in this market, and the reason is simple: orforglipron is a new small molecule under patent, so there is no compounded version to undercut it.
Next steps
Rybelsus prices
Find more like it
Side effectsDose changeInjection techniqueCost and insuranceExercise and strengthAlcoholHow it worksThe trialsNauseaConstipation
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.

















